BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-11
212 industry Phase 2/3 trial readout(s) and 32 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-11 est. | P1/P2 | Cortice Biosciences, Inc. | NCT01933815 Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma | Glioblastoma Multiforme | suspended | 92 |
| 2024-11 | P2 | Candel Therapeutics, Inc. CADL | NCT02768363 Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | Prostate Cancer | active not recruiting | 187 |
| 2024-11 est. | P3 | Surgimab | NCT03659448 Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Colorectal Neoplasms | recruiting | 300 |
| 2024-11 est. | P1/P2 | Kartos Therapeutics, Inc. | NCT03787602 Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | Merkel Cell Carcinoma | unknown | 115 |
| 2024-11 est. | P2 | Silk Road Therapies, Inc. | NCT04186559 Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers | Behcet Syndrome; Behcet Disease | unknown | 60 |
| 2024-11 est. | P1/P2 | Telios Pharma, Inc. | NCT04669067 TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Acute Myeloid Leukemia | unknown | 18 |
| 2024-11 est. | P3 | MaaT Pharma | NCT04769895 MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients | Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD | unknown | 66 |
| 2024-11 est. | P1/P2 | Direct Biologics, LLC | NCT05116761 ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome | Covid19; Postviral Syndrome; Dyspnea | withdrawn | |
| 2024-11 est. | P1/P2 | Myeloid Therapeutics | NCT05138458 A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | Lymphoma, T-Cell, Peripheral; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Adoptive Cellular Immu | suspended | 40 |
| 2024-11 est. | P2 | Bazell Pharma AG | NCT05214599 Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (Eo | Eosinophilic Esophagitis | withdrawn | |
| 2024-11 est. | P2 | Vitti Labs, LLC | NCT05387239 Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19 | Pulmonary Fibrosis; COVID-19 Respiratory Infection | suspended | 20 |
| 2024-11 est. | P2 | Onconic Therapeutics Inc. | NCT05475184 A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor | Ovarian Cancer | unknown | 58 |
| 2024-11 est. | P2 | Kira Pharmacenticals (US), LLC. | NCT05476887 To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104 | Paroxysmal Nocturnal Hemoglobinuria | unknown | 35 |
| 2024-11 est. | P1/P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05625919 A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) | Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) | unknown | 54 |
| 2024-11 est. | P3 | EMS | NCT05684380 Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER) | Allergic Rhinitis | unknown | 514 |
| 2024-11 est. | P2 | Golo | NCT05844644 The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes | Type 2 Diabetes; Obese; Overweight; Prediabetes | unknown | 100 |
| 2024-11 est. | P2 | Amydis Inc. | NCT06223048 A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma | Primary Open Angle Glaucoma | unknown | 50 |
| 2024-11 est. | P2 | DermBiont, Inc. | NCT06409195 A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers | Non-Melanoma Skin Cancers | unknown | 50 |
| 2024-11 est. | P2 | Sao Thai Duong Joint Stock Company | NCT06657495 To Evaluate the Safety and Efficacy of TD0015 Pilulae in Patients with Knee Osteoarthritis | Knee Osteoarthritis | unknown | 90 |
| 2024-11-01 | P3 | Pfizer PFE | NCT04188509 Open-Label Extension of Voxelotor | Sickle Cell Disease | terminated | 162 |
| 2024-11-01 | P3 | Shanghai Biomabs Pharmaceutical Co., Ltd. | NCT04591275 Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . | Postmenopausal Osteoporosis | completed | 278 |
| 2024-11-01 est. | P2 | Celltex Therapeutics Corporation | NCT05017298 Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells | Corona Virus Infection; Covid19 | unknown | 30 |
| 2024-11-01 | P2 | Remedy | NCT05067244 A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) | Post Traumatic Stress Disorder | completed | 10 |
| 2024-11-01 est. | P2 | AGO Research GmbH | NCT05126342 Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi | Recurrent Ovarian Cancer; Recurrent Fallopian Tube Cancer; Primary Peritoneal Cancer | withdrawn | |
| 2024-11-01 | P2 | BioVersys AG | NCT05685615 PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB | Ventilator Associated Pneumonia | completed | 39 |
| 2024-11-01 est. | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT05938179 A Study of HS-10353 in Adult Participants With Major Depressive Disorder | Major Depressive Disorder (MDD) | unknown | 144 |
| 2024-11-01 | P2 | Novartis Pharmaceuticals NVS | NCT06142383 A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure | Heart Failure | terminated | 136 |
| 2024-11-01 | P2 | InventisBio Co., Ltd | NCT06278350 Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis | Plaque Psoriasis | completed | 161 |
| 2024-11-01 | P3 | GlaxoSmithKline | NCT06374394 A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in A | Respiratory Syncytial Virus Infections | completed | 841 |
| 2024-11-03 | P3 | Aldeyra Therapeutics, Inc. ALDX | NCT06424444 A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease | Dry Eye Disease | completed | 421 |
| 2024-11-04 | P1/P2 | Bristol-Myers Squibb BMY | NCT03377361 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of | Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm | completed | 325 |
| 2024-11-04 | P1/P2 | Epizyme, Inc. | NCT04179864 A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer | Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer | terminated | 102 |
| 2024-11-04 | P2 | AstraZeneca AZN | NCT05246514 A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC | HER2-mutant Non-Small Cell Lung Cancer | active not recruiting | 72 |
| 2024-11-04 | P2 | Novartis Pharmaceuticals NVS | NCT05445843 Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell L | Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expres | active not recruiting | 95 |
| 2024-11-04 | P3 | LG Chem | NCT05586958 Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients | Gout; Hyperuricemia; Gout Flare; Tophi | completed | 354 |
| 2024-11-04 | P3 | Viridian Therapeutics, Inc. VRDN | NCT06021054 An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) | Thyroid Eye Disease | completed | 188 |
| 2024-11-04 | P2 | River 2 Renal Corp. | NCT06264310 To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF) | Heart Failure; Worsening Heart Failure (WHF) | completed | 33 |
| 2024-11-06 | P2 | Novartis Pharmaceuticals NVS | NCT03474965 Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | Sickle Cell Disease (SCD) | completed | 117 |
| 2024-11-06 | P2/P3 | Janssen Pharmaceutical K.K. | NCT04630145 A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium | Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) | completed | 129 |
| 2024-11-06 | P3 | AbbVie ABBV | NCT05028569 Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | Episodic Migraine | terminated | 775 |
| 2024-11-06 | P2 | Hoffmann-La Roche | NCT05151731 A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema | Diabetic Macular Edema | completed | 394 |
| 2024-11-06 | P2 | Takeda TAK | NCT05353985 A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet | Celiac Disease | completed | 153 |
| 2024-11-06 | P3 | Sanofi SNY | NCT05405166 SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM | Plasma Cell Myeloma Recurrent | active not recruiting | 531 |
| 2024-11-06 | P3 | LG Chem | NCT05431933 Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Sche | Poliomyelitis; Vaccine Reaction | completed | 2001 |
| 2024-11-06 | P3 | Merck Sharp & Dohme LLC MRK | NCT06212752 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastati | Metastatic Non-small Cell Lung Cancer | active not recruiting | 39 |
| 2024-11-06 | P2 | Clexio Biosciences Ltd. | NCT06262607 A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica | Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (NP) | completed | 59 |
| 2024-11-06 | P3 | Haisco Pharmaceutical Group Co., Ltd. | NCT06391931 A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patient | Anesthesia | completed | 190 |
| 2024-11-07 | P1/P2 | Bristol-Myers Squibb BMY | NCT03369223 A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | Advanced Cancer | completed | 356 |
| 2024-11-07 | P1/P2 | Lexeo Therapeutics LXEO | NCT03634007 Gene Therapy for APOE4 Homozygote of Alzheimer's Disease | Alzheimer Disease; Early Onset Alzheimer Disease | completed | 15 |
| 2024-11-07 | P3 | Novartis Pharmaceuticals NVS | NCT03769168 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA) | Juvenile Psoriatic Arthritis; Enthesitis Related Arthritis | completed | 55 |
| 2024-11-07 | P2 | Mapreg | NCT03870776 RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode | Depression | completed | 126 |
| 2024-11-07 | P2 | Fulcrum Therapeutics FULC | NCT04264442 Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE) | Facioscapulohumeral Muscular Dystrophy (FSHD) | terminated | 76 |
| 2024-11-07 | P2 | Novartis Pharmaceuticals NVS | NCT04452877 A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | Carcinoma, Non-Small-Cell Lung | completed | 40 |
| 2024-11-07 | P3 | Bristol-Myers Squibb BMY | NCT04908189 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Bio | Psoriatic Arthritis | active not recruiting | 729 |
| 2024-11-07 | P1/P2 | Armata Pharmaceuticals, Inc. ARMP | NCT05184764 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia | Bacteremia; Staphylococcus Aureus; Staphylococcus Aureus Bacteremia; Bacteremia Staph; Bacteremia Du | completed | 56 |
| 2024-11-07 | P3 | Bayer | NCT05850520 A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelli | Macular Edema Secondary to Retinal Vein Occlusion | completed | 892 |
| 2024-11-07 | P2 | Affimed GmbH | NCT05883449 Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL | Relapsed or Refractory Hodgkin Lymphoma; Peripheral T Cell Lymphoma | terminated | 25 |
| 2024-11-07 | P3 | Outlook Therapeutics, Inc. OTLK | NCT06190093 A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Neovascular Age-related Macular Degeneration; Age-Related Macular Degeneration; Wet Macular Degenera | completed | 400 |
| 2024-11-08 | P1/P2 | Sanofi SNY | NCT03284957 Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Posi | Breast Cancer | terminated | 136 |
| 2024-11-08 | P1/P2 | Eli Lilly and Company LLY | NCT03899792 A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | Medullary Thyroid Cancer; Infantile Myofibromatosis; Infantile Fibrosarcoma; Papillary Thyroid Cance | active not recruiting | 36 |
| 2024-11-08 | P3 | ModernaTX, Inc. | NCT05330975 A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age | Respiratory Syncytial Virus | completed | 3317 |
| 2024-11-08 | P3 | Janssen Research & Development, LLC | NCT05550532 A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Curre | Depressive Disorder, Major; Anhedonia | completed | 444 |
| 2024-11-08 | P2 | Kezar Life Sciences, Inc. | NCT05781750 A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) | Lupus Nephritis | terminated | 84 |
| 2024-11-08 | P2 | MC2 Therapeutics | NCT06132919 Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) | Vulvar Lichen Sclerosus | completed | 33 |
| 2024-11-08 | P3 | Colgate Palmolive CL | NCT06486974 Efficacy of Manual Toothbrushes in Removing Tooth Stains | Tooth Discoloration | completed | 80 |
| 2024-11-08 | P2 | Asceneuron S.A. | NCT06677203 Study of ASN51 in Adults With Early Alzheimer's Disease | Alzheimer Disease | terminated | 123 |
| 2024-11-10 est. | P2 | Gannex Pharma Co., Ltd. | NCT05118360 Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH | Nonalcoholic Steatohepatitis (NASH) | withdrawn | |
| 2024-11-10 | P1/P2 | 23andMe, Inc. | NCT06290388 Study of 23ME-01473 in Patients With Advanced Solid Malignancies | Solid Tumor | terminated | 5 |
| 2024-11-11 | P2 | Taiho Oncology, Inc. | NCT04189445 Futibatinib in Patients With Specific FGFR Aberrations | Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myelo | terminated | 115 |
| 2024-11-11 | P2 | Sun Pharmaceutical Industries Limited | NCT04684485 To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis | Dermatitis, Atopic | completed | 250 |
| 2024-11-11 est. | P2 | Aphaia Pharma US LLC | NCT05385978 A Study of Distal Jejunal-release Dextrose in Obese Participants | Obese | unknown | 150 |
| 2024-11-11 | P3 | Sanofi SNY | NCT05526521 A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria | Chronic Spontaneous Urticaria | completed | 15 |
| 2024-11-11 | P1/P2 | Lubris Bio Pty Ltd | NCT06520202 RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE | Sjogren's Syndrome With Dry Eye | terminated | 8 |
| 2024-11-11 | P3 | HTA Co., Ltd. | NCT07119242 Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs | NETs | active not recruiting | 95 |
| 2024-11-11 | P2 | Daewon Pharmaceutical Co., Ltd. | NCT07319520 Clinical Trial to Evaluate the Efficacy and Safety of DW4902 | Myoma of Uterus | completed | 71 |
| 2024-11-12 | P1/P2 | Bristol-Myers Squibb BMY | NCT01658878 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advan | Hepatocellular Carcinoma | completed | 657 |
| 2024-11-12 | P3 | Sarepta Therapeutics, Inc. SRPT | NCT02500381 Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy | completed | 228 |
| 2024-11-12 | P3 | Pfizer PFE | NCT03573882 Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031 | Sickle Cell Disease | terminated | 179 |
| 2024-11-12 | P3 | PharmaEssentia | NCT04285086 Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Essential Thrombocythemia | active not recruiting | 174 |
| 2024-11-12 | P2 | Gilead Sciences GILD | NCT04971785 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | completed | 457 |
| 2024-11-12 | P3 | Novartis Pharmaceuticals NVS | NCT05089656 Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) | Type 2 Spinal Muscular Atrophy | completed | 126 |
| 2024-11-12 | P1/P2 | Arrowhead Pharmaceuticals ARWR | NCT05292950 Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease | Asthma; Chronic Obstructive Pulmonary Disease | terminated | 78 |
| 2024-11-12 | P2 | Teva Branded Pharmaceutical Products R&D, Inc. | NCT05499130 A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | Crohn Disease; Colitis, Ulcerative | completed | 290 |
| 2024-11-12 | P2 | Smilebiotek Zhuhai Limited | NCT05536752 QA102 Phase II Study in Subjects With Dry AMD | Dry Age-related Macular Degeneration | completed | 150 |
| 2024-11-12 | P1/P2 | Shanghai Juncell Therapeutics | NCT06120712 A Study of GC101 TIL in Advanced Melanoma (BZ) | Tumor Infiltrating Lymphocytes; Safety; Melanoma; Efficacy; Adverse Drug Event | completed | 18 |
| 2024-11-13 | P3 | Syros Pharmaceuticals | NCT04797780 Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome | Myelodysplastic Syndromes | terminated | 246 |
| 2024-11-13 | P1/P2 | Repare Therapeutics | NCT04972110 Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors | Advanced Solid Tumor, Adult | terminated | 156 |
| 2024-11-13 | P3 | Novo Nordisk A/S NVO | NCT05306418 A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors | Haemophilia A With or Without Inhibitors | completed | 70 |
| 2024-11-13 | P3 | Eli Lilly and Company LLY | NCT05822830 A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Obesity; Overweight | completed | 751 |
| 2024-11-13 | P2 | GH Research Ireland Limited | NCT05839509 Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | Bipolar II Disorder | terminated | 6 |
| 2024-11-13 | P2 | Sanofi SNY | NCT06073119 A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis | Psoriasis | completed | 221 |
| 2024-11-13 | P2 | Akeso | NCT06092762 A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | completed | 180 |
| 2024-11-14 | P2 | InFlectis BioScience | NCT05508074 Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol) | Amyotrophic Lateral Sclerosis; ALS | completed | 51 |
| 2024-11-14 | P2 | ApcinteX Ltd | NCT05789524 The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B | Hemophilia a; Hemophilia B | terminated | 60 |
| 2024-11-14 | P2 | ApcinteX Ltd | NCT05789537 A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors | Hemophilia B with Inhibitor; Hemophilia B | terminated | 3 |
| 2024-11-14 | P3 | Alcon Research ALC | NCT06444529 A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness | Ocular Redness | completed | 159 |
| 2024-11-14 | P3 | Sedana Medical | NCT06809218 A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous Propofol | Post-Intensive Care Syndrome; Sedation | active not recruiting | 312 |
| 2024-11-15 | P2 | Istari Oncology, Inc. | NCT04577807 LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma | Melanoma | completed | 27 |
| 2024-11-15 | P2 | Verastem, Inc. VSTM | NCT04625270 A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation | Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer | active not recruiting | 225 |
| 2024-11-15 | P3 | Axsome Therapeutics, Inc. AXSM | NCT05113745 A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE) | Narcolepsy; Cataplexy; Excessive Daytime Sleepiness | completed | 68 |
| 2024-11-15 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05367687 A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Ris | Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Cu | completed | 251 |
| 2024-11-15 | P2 | ModernaTX, Inc. | NCT05584202 Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | SARS-CoV-2 | terminated | 68 |
| 2024-11-15 | P3 | Alexion Pharmaceuticals, Inc. | NCT05778071 Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism | Chronic Hypoparathyroidism; Endocrine System Diseases; Parathyroid Diseases | active not recruiting | 165 |
| 2024-11-15 | P2 | Artios Pharma Ltd | NCT05798611 Study of ART0380 in Patients With Biologically Selected Solid Tumors | Advanced Solid Tumor; Recurrent Endometrial Cancer; Metastatic Cancer | terminated | 36 |
| 2024-11-15 | P2 | Reata, a wholly owned subsidiary of Biogen | NCT05895552 A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | terminated | 209 |
| 2024-11-15 est. | P2 | NeuTherapeutics | NCT06186531 PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health | Menopause; Hot Flashes | unknown | 132 |
| 2024-11-15 | P3 | Janssen Research & Development, LLC | NCT06220604 A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) | Plaque Psoriasis | active not recruiting | 731 |
| 2024-11-15 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06393348 Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i. | Type 2 Diabetes | completed | 155 |
| 2024-11-15 | P3 | Huabo Biopharm Co., Ltd. | NCT06477237 Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis | Psoriasis | completed | 408 |
| 2024-11-15 est. | P1/P2 | Frontera Therapeutics | NCT06492876 Gene Therapy for DME | Diabetic Macular Edema | recruiting | 78 |
| 2024-11-17 est. | P3 | Beijing Health Guard Biotechnology, Inc | NCT06207175 A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine | Human Papillomavirus Infection | unknown | 1260 |
| 2024-11-18 | P3 | Grünenthal GmbH | NCT05248386 Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis | Osteoarthritis | completed | 469 |
| 2024-11-18 | P2 | COMPASS Pathways CMPS | NCT05481736 Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | Anorexia Nervosa | completed | 32 |
| 2024-11-18 | P2 | Chipscreen Biosciences, Ltd. | NCT05519865 A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC | Non Small Cell Lung Cancer | completed | 118 |
| 2024-11-18 | P3 | AstraZeneca AZN | NCT05555290 PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction | Asthma | completed | 190 |
| 2024-11-18 | P1/P2 | Biomea Fusion Inc. BMEA | NCT05731544 Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) | Type 2 Diabetes Mellitus | completed | 443 |
| 2024-11-18 | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06516068 A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic Cardiomyopathy | active not recruiting | 42 |
| 2024-11-19 | P1/P2 | TCR2 Therapeutics | NCT03907852 Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Per | active not recruiting | 57 |
| 2024-11-19 | P3 | Fulcrum Therapeutics FULC | NCT05397470 Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH) | Facioscapulohumeral Muscular Dystrophy (FSHD) | terminated | 260 |
| 2024-11-19 | P1/P2 | Ichnos Sciences SA | NCT05427812 Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | terminated | 29 |
| 2024-11-19 | P3 | AstraZeneca AZN | NCT05755906 A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Part | Asthma | completed | 374 |
| 2024-11-19 | P2 | Percheron Therapeutics | NCT05938023 A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | terminated | 48 |
| 2024-11-19 | P3 | Invivyd, Inc. IVVD | NCT06039449 A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Expo | COVID-19; SARS-CoV-2 | completed | 790 |
| 2024-11-19 | P2 | Regeneron Pharmaceuticals REGN | NCT06454630 A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants | Venous Thromboembolism | completed | 179 |
| 2024-11-19 | P3 | Prime Gene Therapeutics Co., Ltd. | NCT06587685 A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis | Atopic Dermatitis | recruiting | 472 |
| 2024-11-20 | P2 | Respira Therapeutics, Inc. | NCT04266197 Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study | Pulmonary Arterial Hypertension | completed | 42 |
| 2024-11-20 | P2 | Sun Pharmaceutical Industries Limited | NCT04566666 To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis | Moderate to Severe Plaque Psoriasis | completed | 263 |
| 2024-11-20 | P1/P2 | Suzhou Junde Biotechnology Co., Ltd | NCT04843098 Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | active not recruiting | 108 |
| 2024-11-20 | P3 | Merck Sharp & Dohme LLC MRK | NCT05093933 A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) | Chronic Heart Failure With Reduced Ejection Fraction | completed | 6106 |
| 2024-11-20 | P2 | EMD Serono Research & Development Institute, Inc. | NCT05162586 The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) | Systemic Lupus Erythematosus | completed | 456 |
| 2024-11-20 | P1/P2 | TaiMed Biologics Inc. | NCT05275998 TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals | HIV-1-infection | completed | 51 |
| 2024-11-20 est. | P1/P2 | ViGenCell Inc. | NCT05276076 A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics | Graft Versus Host Disease | unknown | 12 |
| 2024-11-20 | P3 | Hoffmann-La Roche | NCT05415215 A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Partic | Early Breast Cancer; Locally Advanced Breast Cancer; Inflammatory Breast Cancer | completed | 346 |
| 2024-11-20 | P2 | AstraZeneca AZN | NCT05498155 Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer | Breast Cancer | completed | 50 |
| 2024-11-20 | P2 | ImmuneSensor Therapeutics Inc. | NCT05846659 Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies | Oligoprogressive | terminated | 16 |
| 2024-11-20 | P3 | Yangtze River Pharmaceutical Group Co., Ltd. | NCT06904248 Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery | Participants With Acute Moderate to Severe Pain Following Abdominal Surgery | completed | 224 |
| 2024-11-21 | P3 | Novo Nordisk A/S NVO | NCT04865770 A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Tr | Diabetes Mellitus, Type 2; Chronic Kidney Disease | completed | 106 |
| 2024-11-21 | P1/P2 | Omega Therapeutics OHI | NCT05497453 A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene | Hepatocellular Carcinoma; Solid Tumor; Hepatocellular Carcinoma Non-resectable; Hepatocellular Carci | terminated | 24 |
| 2024-11-21 | P3 | Axsome Therapeutics, Inc. AXSM | NCT05557409 A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation | Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation | completed | 408 |
| 2024-11-21 | P2 | Sanofi SNY | NCT05630547 A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis | Multiple Sclerosis | terminated | 174 |
| 2024-11-21 | P2 | Beijing Mabworks Biotech Co., Ltd. | NCT05796206 A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | completed | 123 |
| 2024-11-21 | P1/P2 | Servier Bio-Innovation LLC | NCT05921760 Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | IDH1-mutant Cholangiocarcinoma | terminated | 7 |
| 2024-11-21 | P2 | Laboratoires Thea | NCT06394973 Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension | Glaucoma; Ocular Hypertension | completed | 161 |
| 2024-11-22 | P1/P2 | NeoImmuneTech | NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Any Advanced Solid Tumors; Triple Negative Breast Cancer; Non Small Cell Lung Cancer; Small Cell Lun | completed | 215 |
| 2024-11-22 | P3 | Otsuka Beijing Research Institute | NCT05583474 OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects | Open Angle Glaucoma or Ocular Hypertension | completed | 204 |
| 2024-11-22 | P3 | Meiji Seika Pharma Co., Ltd. | NCT05887908 Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acut | Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI; AP | completed | 614 |
| 2024-11-22 | P2 | Chengdu Suncadia Medicine Co., Ltd. | NCT05905458 A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleo | Chronic Hepatitis B | completed | 54 |
| 2024-11-22 | P3 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT06076486 A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain | Endometriosis | completed | 202 |
| 2024-11-22 | P2 | Zydus Lifesciences Limited | NCT06398808 A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or | Ulcerative Colitis | completed | 24 |
| 2024-11-22 | P2/P3 | Biomed Industries, Inc. | NCT06849973 To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome | Rett Syndrome | completed | 187 |
| 2024-11-23 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05699408 To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Dru | Type 2 Diabetes | completed | 513 |
| 2024-11-23 est. | P3 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT06561594 To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection | Idiopathic Hypogonadotropic Hypogonadism | not yet recruiting | 60 |
| 2024-11-24 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT05950516 Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes | Type 2 Diabetes | unknown | 478 |
| 2024-11-25 | P2 | Bausch Health Americas, Inc. | NCT03596905 Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C) | Irritable Bowel Syndrome With Constipation | completed | 218 |
| 2024-11-25 | P3 | Wockhardt | NCT04979806 Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) | Complicated Urinary Tract Infection; Acute Pyelonephritis | completed | 530 |
| 2024-11-25 | P2 | Cognition Therapeutics CGTX | NCT05225415 Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies | Dementia With Lewy Bodies | completed | 130 |
| 2024-11-25 | P1/P2 | Avidity Biosciences, Inc. | NCT05670730 Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping | Duchenne Muscular Dystrophy; Exon 44 | completed | 70 |
| 2024-11-26 | P2 | Sanofi SNY | NCT03996291 Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis | Relapsing Multiple Sclerosis | completed | 125 |
| 2024-11-26 | P2 | Clarity Pharmaceuticals Ltd | NCT04438304 A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) | Neuroendocrine Tumors | completed | 45 |
| 2024-11-26 | P3 | Alexion Pharmaceuticals, Inc. | NCT04557735 Study of Ravulizumab in Pediatric Participants With HSCT-TMA | Thrombotic Microangiopathy | completed | 41 |
| 2024-11-26 | P1/P2 | Siolta Therapeutics, Inc. | NCT05003804 Allergic Disease Onset Prevention Study | Atopic Dermatitis; Type 1 Hypersensitivity | completed | 283 |
| 2024-11-26 | P3 | RemeGen Co., Ltd. | NCT05737160 Study of Telitacicept in Generalized Myasthenia Gravis | Myasthenia Gravis, Generalized | completed | 114 |
| 2024-11-26 | P3 | Visirna Therapeutics HK Limited | NCT05902598 A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome | Familial Chylomicronemia Syndrome | completed | 37 |
| 2024-11-26 | P2 | Genome & Company | NCT05998447 GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer | Biliary Tract Cancer | terminated | 10 |
| 2024-11-26 | P3 | BioNTech SE BNTX | NCT06178991 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. | Influenza; COVID-19 | completed | 8795 |
| 2024-11-26 | P2 | Shanghai Hutchison Pharmaceuticals Limited | NCT06202378 Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke | Acute Ischemic Stroke | completed | 270 |
| 2024-11-26 | P3 | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | NCT06460493 Effect of Ensifentrine Treatment on CAT Score | COPD | completed | 20 |
| 2024-11-27 | P3 | ITM Solucin GmbH | NCT03049189 Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients | Neuroendocrine Tumors | active not recruiting | 324 |
| 2024-11-27 | P2 | Tasly Pharmaceutical Group Co., Ltd | NCT04983043 Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure | Chronic Heart Failure With Reduced Ejection Fraction | completed | 228 |
| 2024-11-27 | P1/P2 | Lassen Therapeutics 1 PTY LTD | NCT05331300 A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Th | Pulmonary Fibrosis; Thyroid Eye Disease | completed | 75 |
| 2024-11-27 | P3 | Axsome Therapeutics, Inc. AXSM | NCT05550207 Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) | Migraine | completed | 100 |
| 2024-11-27 | P2 | Novo Nordisk A/S NVO | NCT06064006 A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin | Obesity; Overweight | completed | 125 |
| 2024-11-28 | P3 | Eli Lilly and Company LLY | NCT04232553 A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | Crohn's Disease | active not recruiting | 996 |
| 2024-11-28 | P3 | Janssen Research & Development, LLC | NCT04673357 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | Crohn Disease | completed | 101 |
| 2024-11-28 | P2 | Alterity Therapeutics ATHE | NCT05109091 Study of ATH434 in Participants with Multiple System Atrophy | Multiple System Atrophy | completed | 77 |
| 2024-11-28 | P3 | Amgen AMGN | NCT05398445 A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) | Atopic Dermatitis | completed | 769 |
| 2024-11-28 | P2 | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | NCT05611671 A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC | Inflammatory Bowel Diseases; Colitis, Ulcerative | completed | 280 |
| 2024-11-28 | P2 | Ophirex, Inc. | NCT05717062 Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO) | Snakebite; Envenoming, Snake | completed | 140 |
| 2024-11-28 | P3 | Guerbet | NCT06057168 Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas | Brain Tumor, Primary; Brain Tumor, Recurrent | completed | 138 |
| 2024-11-28 | P3 | Polisorb Joint Stock Company | NCT07929181 Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis | Atopic Dermatitis | completed | 161 |
| 2024-11-29 | P3 | NovoCure GmbH NVCR | NCT02831959 Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer | Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | completed | 298 |
| 2024-11-29 | P1/P2 | AstraZeneca AZN | NCT03742102 A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | active not recruiting | 243 |
| 2024-11-29 | P3 | Amicus Therapeutics | NCT04049760 Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease | Fabry Disease | completed | 16 |
| 2024-11-29 | P3 | Hoffmann-La Roche | NCT04182204 A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine | Diffuse Large B-Cell Lymphoma | completed | 270 |
| 2024-11-29 | P1/P2 | Geneos Therapeutics | NCT04251117 GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC | HCC | active not recruiting | 36 |
| 2024-11-29 | P3 | Teva Branded Pharmaceutical Products R&D, Inc. | NCT04464707 A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age | Migraine | completed | 292 |
| 2024-11-29 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04859582 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-85 | Stomach Neoplasms | withdrawn | |
| 2024-11-29 | P3 | Novartis Pharmaceuticals NVS | NCT05386680 Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Disco | Spinal Muscular Atrophy | completed | 27 |
| 2024-11-29 | P1/P2 | Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA | NCT05574010 A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it) | Celiac Disease | terminated | 128 |
| 2024-11-29 est. | P2 | AnaptysBio, Inc. ANAB | NCT06041269 A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR) | Rheumatoid Arthritis | active not recruiting | 420 |
| 2024-11-29 | P2 | Shanxi Kangbao Biological Product Co., Ltd. | NCT06061536 Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. | HIV | completed | 64 |
| 2024-11-29 | P3 | Olive Healthcare | NCT06597175 Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy | Breast Cancer; Breast Tumor; Mammary Carcinoma, Human | completed | 300 |
| 2024-11-30 | P1/P2 | Cyteir Therapeutics, Inc. | NCT03997968 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | Malignancy; Non-hodgkin Lymphoma; Multiple Myeloma; Breast Cancer; Ovarian Cancer; Soft Tissue Sarco | completed | 169 |
| 2024-11-30 | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04284488 Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors | Advanced Solid Tumor | terminated | 40 |
| 2024-11-30 | P1/P2 | Otsuka Pharmaceutical Co., Ltd. | NCT04362007 A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell | terminated | 8 |
| 2024-11-30 est. | P1/P2 | NexImmune Inc. | NCT04505813 Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | Relapsed Refractory Multiple Myeloma | suspended | 9 |
| 2024-11-30 est. | P1/P2 | LintonPharm Co.,Ltd. | NCT04799847 Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | Bladder Cancer | unknown | 161 |
| 2024-11-30 | P3 | Hutchison Medipharma Limited | NCT04923945 Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients | Non-small Cell Lung Cancer Metastatic | completed | 203 |
| 2024-11-30 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT04961710 Extension Study of Hetrombopag in Severe Aplastic Anemia | Treatment-naive Severe Aplastic Anemia | unknown | 157 |
| 2024-11-30 | P3 | Ipsen | NCT05027802 A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossific | Fibrodysplasia Ossificans Progressiva (FOP) | completed | 61 |
| 2024-11-30 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05349409 A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers | Advanced Solid Tumors | unknown | 212 |
| 2024-11-30 est. | P2/P3 | Shaperon | NCT05352347 Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients | COVID-19 Pneumonia | unknown | 1134 |
| 2024-11-30 est. | P1/P2 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | NCT05447494 Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease | Gaucher Disease, Type 1; Gaucher Disease, Type 3 | unknown | 40 |
| 2024-11-30 est. | P2 | WestVac Biopharma Co., Ltd. | NCT05465902 Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster | COVID-19; SARS-CoV-2 Infection | withdrawn | |
| 2024-11-30 | P2 | Hutchmed HCM | NCT05467943 Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma With EZH2 | completed | 42 |
| 2024-11-30 | P2 | Stella Pharma Corporation | NCT05601232 A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA | Unresectable Angiosarcoma | active not recruiting | 10 |
| 2024-11-30 | P2 | Biocity Biopharmaceutics Co., Ltd. | NCT05687890 A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease | Diabetic Kidney Disease; IgA Nephropathy | unknown | 255 |
| 2024-11-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05923008 A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Solid Tumor | unknown | 182 |
| 2024-11-30 est. | P2 | Akeso | NCT05960955 Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | recruiting | 90 |
| 2024-11-30 | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05991349 A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors | Solid Tumor | completed | 36 |
| 2024-11-30 est. | P3 | Huons Biopharma | NCT06205797 To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) | Glabellar Lines | unknown | 312 |
| 2024-11-30 est. | P2 | Grand Medical Pty Ltd. | NCT06548854 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Charac | Sepsis | unknown | 180 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.